Hunan Cancer Hospital

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Employees: -

Market Cap: -

Website: http://www.hnca.org.cn

Clinical Trials

Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer

Phase 2

Conditions: Uterine Cancer
Advanced Non Small Cell Lung Cancer
Soft Tissue Sarcoma

Interventions: Drug: PD-1 inhibitor
Drug: Apatinib

First Posted Date: 2020-01-27

Last Posted Date: 2020-01-27

Lead Sponsor: Hunan Cancer Hospital

Target Recruit Count: 120

Registration Number: NCT04239443

Locations: 🇨🇳
Hunan cancer Hospital, Changsha, Hunan, China

Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC

Phase 2

Conditions: Small-cell Lung Cancer
Small Cell Lung Carcinoma
Small Cell Lung Cancer Recurrent
Small Cell Lung Cancer Extensive Stage

Interventions: Drug: PD-1 inhibitor
Drug: Metformin

First Posted Date: 2019-06-21

Last Posted Date: 2019-08-28

Lead Sponsor: Hunan Cancer Hospital

Target Recruit Count: 68

Registration Number: NCT03994744

Locations: 🇨🇳
Hunan Cancer hospital, Changsha, Hunan, China

A Study of Niraparib in Combination With Brivanib in Recurrent Ovarian Cancer

Phase 1

Conditions: Ovarian Cancer

Interventions: Drug: niraparib
Drug: Brivanib

First Posted Date: 2019-03-29

Last Posted Date: 2019-03-29

Lead Sponsor: Hunan Cancer Hospital

Target Recruit Count: 24

Registration Number: NCT03895788

Locations: 🇨🇳
Jing Wang, Changsha, Hunan, China

Anlotinib Plus Docetaxel for the Treatment of EGFR Wild-type Advanced Non-small-cell Lung Cancer

Phase 2

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Anlotinib Plus Docetaxel
Drug: Docetaxel

First Posted Date: 2018-08-10

Last Posted Date: 2020-01-07

Lead Sponsor: Hunan Cancer Hospital

Target Recruit Count: 84

Registration Number: NCT03624309

Locations: 🇨🇳
Hunan Cancer hospital, Changsha, Hunan, China

PEG-ASP+Gemoxd vs. PEG-ASP+CHOP as First-line Chemotherapy to Treatment NK/T-cell Lymphoma With Early Stage

Phase 2

Conditions: Lymphoma

Interventions: Drug: pegaspargase
Drug: Gemcitabine
Drug: Cyclophosphamide
Drug: Oxaliplatin
Drug: Doxorubicin
Drug: Dexamethasone
Drug: Vincristine
Radiation: IMRT
Drug: Prednisone

First Posted Date: 2016-09-29

Last Posted Date: 2020-01-28

Lead Sponsor: Hunan Cancer Hospital

Target Recruit Count: 100

Registration Number: NCT02918747

Locations: 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy